We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Rapid growth seen for opioid-induced constipation market

Report: Rapid growth seen for opioid-induced constipation market

October 14, 2013
CenterWatch Staff

The opioid-induced constipation (OIC) global market will increase significantly from $144.42 million in 2012 to $1.98 billion by 2017, at a compound annual growth rate (CAGR) of 31.9%, according to forecasts from research and consulting firm GlobalData.

GlobalData reports the European Union (EU) has contributed to the majority of sales, generating an estimated $75.4 million in 2012. While Germany was the largest market in the same year, with a share of $41.5 million, the majority of sales will come from the U.S. in 2017, thanks to its possession of more than 90% of the market with a share of $1.79 billion.

The boost in the global market comes from the introduction of several highly targeted, oral, peripherally acting mu-opioid receptor antagonist (PAMORA) therapies, such as AstraZeneca's naloxegol, Cubist's bevenopran and Salix's oral Relistor.

An additional market driver will be the increase in the number of OIC sufferers, due to overall population growth and continued use of opioids for the treatment of chronic non-cancer pain.

Claire Gibson, Ph.D., GlobalData's analyst covering cardiovascular and metabolic disorders, said, "OIC remains a hugely untapped market with little competition among players in the pharmaceutical arena, especially as the first pharmacological treatment only became licensed in 2008. As of September, there are currently only two EU and FDA-approved treatments available. However, the OIC market boasts a commercially attractive patient population size, as well as the scope for companies to seek accelerated approval, enabling a potentially faster and more cost-effective R&D program."

Still, there is a lack of patient and physician awareness of OIC, which could be a major barrier to any further market growth.

Gibson said, "Improving diagnosis and increasing the awareness of new treatments are essential in boosting the drug-treatment rate for OIC. The current market is dominated by inexpensive, widely available laxatives, and despite a lack of strong evidence and poor clinical efficacy surrounding these products, they are currently broadly accepted as the mainstay of constipation relief. The potential success of OIC therapies over such laxatives will depend on extensive marketing," said Gibson.

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing